Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Landscape: Trends and Market Share to 2029

Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Will the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Evolve in Terms of Growth and Size by 2029?

The market for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer has seen a consistent expansion in recent times. Projected to increase from $1.25 billion in 2024 to $1.31 billion in 2025, it’s expected to experience a compound annual growth rate (CAGR) of 4.8%. Key factors attributing to this steady surge during the historical period include the escalating use of companion diagnostics, a heightening awareness about HER2 biomarkers among oncologists, an amplified emphasis on tailored cancer treatments, growing interest in antibody-drug conjugates, and an increase in reimbursements for targeted therapies.

Steady growth is anticipated in the global market for HER2-positive gastric cancer, with projected expansion to $1.57 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 4.6%. Factors advocating this growth during the forecast period encompass a surge in the presence of molecular diagnostic laboratories, escalating awareness drives for gastric cancer findings, increased application of next-generation sequencing (NGS), rising demand for outpatient services for cancer treatment, and mounting worldwide regulatory confirmations for HER2 medicines. Enhancing treatment sequences, application of nanotechnology in medication distribution, usage of artificial intelligence in HER2 diagnosis, improving antibody-dependent cellular cytotoxicity, and progress in immunotherapy combinations are among the major trends in the forecast period.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp

What factors are expected to fuel Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer market growth in the coming years?

The human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market is poised to expand, fueled by the increasing application of targeted cancer therapy. This therapeutic strategy, also referred to as personalized medicine, employs specific drugs or substances to hinder cancer growth by targeting specific molecules that promote tumor advancement. The surge in the utilization of targeted therapy is primarily attributed to breakthroughs in genetic profiling, enabling more accurate treatments in line with the distinct tumor traits of each individual, resulting in heightened efficacy and fewer adverse effects. In the case of HER2-positive gastric cancer, targeted therapy is applied by directly combating the overspread HER2 protein in these tumors, thereby decelerating disease buildup and boosting patient results. As an illustration, in February 2024, the Food and Drug Administration (FDA) sanctioned 16 new personalized medications, as reported by the Personalized Medicine Coalition, a US-based professional membership conglomerate, including 7 cancer drugs and 3 for an assortment of other ailments and conditions in 2023, indicating an upward shift from 6 in 2022. Consequently, the escalating implementation of targeted cancer therapy is steering the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.

What Are The Key Findings From The Segmentation Analysis Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy

2) By Stage: Stage I, Stage II, Stage III, Stage IV

3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:

1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines

2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies

3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy

4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

Which Trends Are Expected To Shape The Future Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?

Leading firms in the HER2-positive gastric cancer market are concentrating their efforts on acquiring approvals for novel remedies such as advanced immunotherapy-enhanced combination regimens. These include the merging of immune checkpoint inhibitors with targeted therapy and chemotherapy to drastically enhance patient results in initial treatment scenarios. The advanced immunotherapy-enhanced combination regimens tactic harnesses the immune system, constrains programmed death (PD)-1 or programmed death (PD)-L1 interaction, targets HER2 receptors, and utilizes chemotherapeutic agents to increase anti-tumor activity and survival rates. For example, in March 2025, the US-based biopharmaceutical firm Merck & Co., Inc. was granted approval by the U.S. Food and Drug Administration (FDA) for pembrolizumab (Keytruda), in alliance with trastuzumab and chemotherapy, as an initial treatment approach for adults with HER2-positive inoperable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma with tumors demonstrating programmed death (PD)-L1 expression. This recently approved combination treatment marked a significant progression in average progression-free survival and total survival compared to standard treatment regimens. With an improved overall response rate of 73% and an extended average response duration, this therapy signifies a significant shift in managing advanced HER2-positive gastric cancers.

What Are The Most Active Companies In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Today?

Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/human-epidermal-growth-factor-receptor-2-her2-positive-gastric-cancer-global-market-report

Which Regional Markets Are Attracting The Most Investment In Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer?

North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=25787&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model